Z. Chang, Important aspects of Toll-like receptors, ligands and their signaling pathways, Inflammation Research, vol.125, issue.Suppl 3, pp.791-808, 2010.
DOI : 10.1007/s00011-010-0208-2

A. Dunne, N. Marshall, and K. Mills, TLR based therapeutics, Current Opinion in Pharmacology, vol.11, issue.4, pp.404-411
DOI : 10.1016/j.coph.2011.03.004

A. Krieg, Toll-like receptor 9 (TLR9) agonists in the treatment of cancer, Oncogene, vol.89, issue.2, pp.161-167, 2008.
DOI : 10.1182/blood-2004-03-1190

G. Weiner, H. Liu, J. Wooldridge, C. Dahle, and A. Krieg, Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization, Proceedings of the National Academy of Sciences, vol.94, issue.20, pp.9410833-10837, 1997.
DOI : 10.1073/pnas.94.20.10833

D. Verthelyi, K. Ishii, M. Gursel, F. Takeshita, and D. Klinman, Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs, The Journal of Immunology, vol.166, issue.4, pp.2372-2377, 2001.
DOI : 10.4049/jimmunol.166.4.2372

G. Hartmann and A. Krieg, Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells, The Journal of Immunology, vol.164, issue.2, pp.944-953, 2000.
DOI : 10.4049/jimmunol.164.2.944

A. Krieg, A. Yi, S. Matson, T. Waldschmidt, G. Bishop et al., CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, vol.374, issue.6522, pp.374546-549, 1995.
DOI : 10.1038/374546a0

C. Kuo, C. Liang, C. Lai, and S. Liang, Involvement of heat shock protein (Hsp) 90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide, J Immunol, issue.10, pp.1786100-6108, 2007.

B. Jahrsdorfer, L. Muhlenhoff, S. Blackwell, M. Wagner, H. Poeck et al., B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides, Clinical Cancer Research, vol.11, issue.4, pp.1490-1499, 2005.
DOI : 10.1158/1078-0432.CCR-04-1890

X. Liang, E. Moseman, M. Farrar, V. Bachanova, D. Weisdorf et al., Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells, Blood, vol.115, issue.24, pp.1155041-5052, 2010.
DOI : 10.1182/blood-2009-03-213363

B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug et al., Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN, J Leukoc Biol, vol.72, issue.1, pp.83-92, 2002.

J. Rubenstein, A. Ferreri, and S. Pittaluga, Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment, Leukemia & Lymphoma, vol.110, issue.sup1, pp.43-51, 2008.
DOI : 10.1182/blood-2007-10-119099

S. Donnou, C. Galand, V. Touitou, C. Sautes-fridman, Z. Fabry et al., Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies, Advances in Hematology, vol.9, issue.17, pp.701-704, 2012.
DOI : 10.1016/j.biopha.2010.01.004

R. Houot and R. Levy, T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy, Blood, vol.113, issue.15, pp.3546-3552, 2009.
DOI : 10.1182/blood-2008-07-170274

G. Weiner, The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides, J Leukoc Biol, vol.68, issue.4, pp.455-463, 2000.

J. Li, W. Song, D. Czerwinski, B. Varghese, S. Uematsu et al., Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself, The Journal of Immunology, vol.179, issue.4, pp.2493-2500, 2007.
DOI : 10.4049/jimmunol.179.4.2493

B. Jahrsdorfer and G. Weiner, CpG oligodeoxynucleotides as immunotherapy in cancer, Update on Cancer Therapeutics, vol.3, issue.1, pp.27-32, 2008.
DOI : 10.1016/j.uct.2007.11.003

G. Weiner, CpG oligodeoxynucleotide-based therapy of lymphoid malignancies, Advanced Drug Delivery Reviews, vol.61, issue.3, pp.263-267, 2009.
DOI : 10.1016/j.addr.2008.12.006

I. Galea, I. Bechmann, and V. Perry, What is immune privilege (not)? Trends Immunol, pp.12-18, 2007.